Cardiologist Azeem Latib, M.D., helped perform the first implant of Abbott's investigational balloon-expandable TAVR valve.
Abbott Announces First-in-Human Implant of Novel Balloon-Expandable TAVR Valve
Nov 28, 2024 08:01
CST Updated
08:01
Abbott
Diagnostic and pharmaceutical product manufacturers
Abbott's Investigational Balloon Expansion for Treating Symptomatic Severe Aortic Stenosis (AS)Transcatheter Aortic Valve Replacement (TAVR)The valve has been used for the first time in treating patients. The company's structural heart product portfolio already includes the Navitor system, a self-expanding TAVR valve.In January 2023ObtainU.S. Food and Drug AdministrationApproval.
Director of Interventional Cardiology and Director of Structural Heart Interventions at Montefiore Health SystemAzeem Latib, M.D.and the Director of Thoracic Surgery at the Minneapolis Heart InstituteVinayak Bapat, M.D.First Human TAVR Implantation with Abbott's New Valve Performed in Tashkent, Uzbekistan.
According to Abbott, this new balloon-expandable TAVR valve is a key step toward the company's goal of developing a software-guided TAVR system, which can continue to provide...Artificial Intelligence (AI)"Lay the Foundation." Advances in software and AI-guided TAVR may help Abbott make a significant impact on the TAVR market, which is primarily dominated by Medtronic's self-expanding Evolut valve and Edwards Lifesciences' balloon-expandable Sapien 3 valve.
"For years, TAVR therapy has benefited both physicians and patients, but doctors have come to understand that one size does not fit all AS patients," Latib said in a statement. "We, along with hospitals around the world, remain focused on helping the growing patient population by researching and offering expanded treatment options that adapt to unique patient needs and anatomies."
"Abbott's experience in the TAVI market gives us a unique understanding of the unmet needs that still exist, and we are leveraging this knowledge to develop future therapies to close this gap," said Senior Vice President of Abbott's Structural Heart business.Sandra LesenfantsWe are able to advance investigational therapies that have the potential to transform patient care by working closely with physicians and researching new innovations.